The Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart (Director Prof. Dr. M. Schwab) is operated by the Robert Bosch Foundation. Since its foundation in 1973, the institute has emerged as Germany's largest and most renowned research unit in the field of clinical pharmacology. Main research activities concentrate on the influence of genetic and non-genetic factors on the variability of drug efficacy and their contributions to disease development. Research areas: Tumor biology, copy number alterations, gene expression profiling, signaling pathway analysis, multiplex protein stainings, in vitro and ex vivo tumor models, tumor therapy This project is part of a research group that seeks to identify new therapy options for lymphoma and patients by bringing together refined molecular biological characterization of tumors and pre-clinical testing of innovative novel drugs.